Drug intelligence / Profile preview

CogniCann

Development stage: Unknown
Lead developer: MGC Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

CogniCann is an oral spray containing a specific ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD) developed for the treatment of dementia and Alzheimer's disease. The formulation is designed to improve behavior and cognition in dementia patients. Phase II clinical trial results showed that CogniCann was safe to use by patients with dementia and demonstrated the ability to inhibit deterioration in the behavior of patients compared to placebo.

Brand names: CogniCann

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on CogniCann.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CogniCann.

Explore the full profile